Molecular Insights and Prognosis Associated With RBM8A in Glioblastoma

Lei Wei†, Chun Zou‡, Liechun Chen‡, Yan Lin§, Lucong Liang‡, Beiquan Hu¶, Yingwei Mao** and Donghua Zou**

†Department of Neurology, The Fifth Affiliated Hospital of Guangxi Medical University, Nanning, China, ‡Department of Neurology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, China, §Department of Medical Oncology, Guangxi Medical University Cancer Hospital, Nanning, China, ¶Department of Neurosurgery, The Fifth Affiliated Hospital of Guangxi Medical University, Nanning, China, **Department of Biology, Pennsylvania State University, University Park, PA, United States

Background: Glioblastoma (GBM) is the most invasive brain tumors, and it is associated with high rates of recurrence and mortality. The purpose of this study was to investigate the expression of RBM8A in GBM and the potential influence of its expression on the disease.

Methods: Levels of RBM8A mRNA in GBM patients and controls were examined in The Cancer Genome Atlas (TCGA), GSE16011 and GSE90604 databases. GBM samples in TCGA were divided into RBM8Ahigh and RBM8Alow groups. Differentially expressed genes (DEGs) between GBM patients and controls were identified, as were DEGs between RBM8Ahigh and RBM8Alow groups. DEGs common to both of these comparisons were analyzed for coexpression and regression analyses. In addition, we identified potential effects of RBM8A on competing endogenous RNAs, immune cell infiltration, methylation modifications, and somatic mutations.

Results: RBM8A is expressed at significantly higher levels in GBM than control samples, and its level correlates with tumor purity. We identified a total of 488 mRNAs that differed between GBM and controls as well as between RBM8Ahigh and RBM8Alow groups, which enrichment analysis revealed to be associated mainly with neuroblast proliferation, and T cell immune responses. We identified 174 mRNAs that gave areas under the receiver operating characteristic curve >0.7 among coexpression module genes, of which 13 were significantly associated with overall survival of GBM patients. We integrated 11 candidate mRNAs through LASSO algorithm, then nomogram, risk score, and decision curve analyses were analyzed. We found that RBM8A may compete with DLEU1 for binding to miR-128-1-5p.

Abbreviations: AUC, Area under the receiver operating characteristic curve; BP, Biological process; C-index, Concordance index; DCA, Decision curve analyses; DEIncRs, Differentially expressed IncRNAs; DEMs, Differentially expressed mRNAs; DEMiRs, Differentially expressed miRNAs; DLEU1, Lymphocytic leukemia 1; DMPs, Differentially methylated probes; EJC, Exon junction complex; GBM, Glioblastoma; GDSC, Genomics of drug sensitivity in cancer; GEO, Gene Expression Omnibus; GO, Gene Ontology; GSEA, gene set enrichment analysis; GSVA, Gene set variation analysis; KEGG, Kyoto Encyclopedia of Genes and Genomes; K-M, Kaplan-Meier; LASSO, Least absolute shrinkage and selection operator regression; MEGENA, Multiscale embedded gene coexpression network analysis; OE, Overexpressing; OS, overall survival; PFN, planar filtered network; RBM, RNA binding motif protein; RBM8A, RNA-binding motif protein 8A; TCGA, The Cancer Genome Atlas; Tcm, Memory T cell; Tregs, T cell regulatory.
and aberrant RBM8A expression was associated with tumor infiltration by immune cells. Some mRNAs associated with GBM prognosis also appear to be methylated or mutated.

Conclusions: Our study strongly links RBM8A expression to GBM pathobiology and patient prognosis. The candidate mRNAs identified here may lead to therapeutic targets against the disease.

Keywords: glioblastoma, RBM8A, cox regression, overall survival, candidate mRNAs

MATERIALS AND METHODS

Data Collection
Data on mRNA sequencing (mRNAseq) and long non-coding RNAs (lncRNAs) from 145 GBM patients and 5 controls was obtained from The Cancer Genome Atlas (TCGA) (https://portal.gdc.cancer.gov/). Gene expression profiles were also acquired from GSE16011 and GSE90604 in the Gene Expression Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/geo/). In GSE16011, mRNAs and lncRNAs were profiled in 276 GBM samples and 8 control samples; in GSE90604, data came from 16 GBM samples and 7 healthy brain samples, which included mRNA expression profiles in GSE90598 and microRNA (miRNA) expression profiles in GSE90603. The Oncomine database was used to analyze RBM8A mRNA expression in human tumors.

RNA Sequencing
The RBM8A-overexpressing T98G cells were constructed using lentiviral expression plasmids and validated using quantitative real-time polymerase chain reaction (qRT-PCR) and western blots, which described in our previous work (Lin et al., 2021). Total RNA was isolated from RBM8A-overexpressing T98G cells and control T98G cells using TRIzol (Thermo Scientific, Uppsala, Sweden) and purified using the RNasy kit (QIAGEN). RNA-Seq libraries were constructed using the TruSeq Stranded mRNA-Seq Library Preparation Kit (Illumina). Samples were sequenced using the Illumina NovaSeq system, generating paired-end reads of 150 bp. Raw sequence reads were converted into fragments per exon kilobase per million mapped reads (FPKM) in order to quantify gene expression.

Difference Analysis
The expression of RBM8A was compared between GBM and normal samples in TCGA, GSE16011, and GSE90598. The “DEseq2” package in R (Love et al., 2014) was used to identify mRNAs and lncRNAs whose expression differed between GBM and controls in TCGA, mRNAs whose expression differed between RBM8A-high and RBM8A-low GBM samples in TCGA, and mRNAs whose expression differed between RBM8A-overexpressing T98G cells and control T98G cells. The “limma” package in R (Ritchie et al., 2015) was used to identify mRNAs and lncRNAs whose expression differed between GBM and controls in GSE16011, mRNAs whose expression differed between GBM and controls in GSE90598, and mRNAs whose expression differed between GBM and controls in GSE90603.

In all analyses, differentially expressed mRNAs (DEmRs), lncRNAs (DElncRs) and miRNAs (DEmiRs) were defined as those whose expression difference was associated with \( p < 0.05 \).
Enrichment of DEmRs in Functions and Pathways
The “clusterProfiler” package in R (Yu et al., 2012) was used to analyze DEmRs for enrichment in Gene Ontology (GO) biological processes (BPs) and in Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. $p < 0.05$ was defined as significant enrichment. Gene set variation analysis (GSVA) was performed using the “GSVA” package in R (Hänzelmann et al., 2013) to order to display enrichment results. The clusterProfiler package was also used to perform gene set enrichment analysis (GSEA) (Subramanian et al., 2005).

Target Prediction
The software IncBase 3 (https://diana.e-ce.uth.gr/Incbasev3) was used to predict the target miRNAs of lncRNAs that were significantly associated with overall survival of GBM patients. The target miRNAs for miRNAs were predicted using miRWalk and TargetScan databases. A network of competing endogenous RNAs (ceRNAs) was constructed based on the predicted negative regulation of miRNAs.

Construction of a Coexpression Network
Multiscale embedded gene coexpression network analysis (MEGENA) was performed using the “MEGENA” package in R (Song and Zhang, 2015). MEGENA builds multiscale networks of potential gene-gene interactions. The default parameters were used to calculate a planar filtered network (PFN) from gene expression correlations in MEGENA.

Construction of a Model to Predict Overall Survival of GBM Patients
Cox regression was used to identify DElncRs and DEmRs associated with overall survival of GBM patients. Survival curves were generated using the “survival” package in R. The “glmnet” package in R (Friedman et al., 2010) was used to integrate potentially prognostic mRNAs into a binomial least absolute shrinkage and selection operator regression (LASSO) model. During LASSO regression, we retained potential predictors with non-zero coefficients and lead to candidate mRNAs. Areas under receiver operating characteristic curves (AUCs) were calculated using the “pROC” package in R (Robin et al., 2011). A prognostic nomogram was constructed via Cox regression to predict 3- and 5-year overall survival of GBM patients in TCGA.

Construction of a Risk Score-Based Prognostic Model
Candidate mRNAs were selected to construct a prognosis model based on a risk score. GBM patients were divided into low- or high-risk groups based on median risk score, and the corresponding Kaplan-Meier curves were generated and compared using the “survival ROC” package in R.

Analysis of Drug Sensitivity
Drug sensitivity of DEmRs in RBM8A high and RBM8A low GBM samples was predicted (in terms of IC50) based on the Genomics of Drug Sensitivity in Cancer database (www.cancerRxgene.org).

Immune Cell Infiltration
Levels of tumor infiltration by immune cells were evaluated using CIBERSORT (https://cibersort.stanford.edu/) and single sample gene set enrichment analysis (ssGSEA) in the “GSVA” package in R. Immune cells expressed as 0 were excluded from the analysis. Differences in levels of immune cell infiltration were calculated between GBM and control samples, as well as between RBM8A high and RBM8A low samples, using the “limma” package in R. We also evaluated potential correlations between candidate mRNAs and immune cells using Pearson correlation.
analysis. Results associated with $p < 0.05$ were considered statistically significant.

**DNA Methylation and Somatic Mutations**

The “cAMP” package and “maftools” package in R (Mayakonda et al., 2018) were used to identify differences in methylation or somatic mutations, respectively, between GBM and control samples in TCGA.

**RESULTS**

**High Expression of RBM8A in GBM**

The flowchart of this study is shown in Figure 1. First, the mRNA expression of RBM8A in human tumors was analyzed using the Oncomine database. Its expression was found to be higher in cancer tissues than in controls (Figure 2A). To identify the potential role of RBM8A on GBM, we characterized RBM8A expression in three datasets: TCGA, GSE16011, and GSE90598. We found that RBM8A was abundantly expressed in GBM tissues but weakly expressed in normal controls (Figure 2B). Interestingly, we found that GBM patients with high expression of RBM8A had poor overall survival based on the optimal threshold for gene expression grouping (Figure 2C). The receiver operating characteristic curves for RBM8A to predict GBM gave AUCs $>0.9$ for all three datasets (Figure 2D). These results indicate that RBM8A expression is upregulated in GBM and may contribute to tumorigenesis. Indeed, expression of RBM8A showed a
positive correlation with GBM tumor purity in TCGA (Figure 2E).

**Identification of RBM8A-Related mRNAs in GBM**

To identify GBM-associated mRNAs, we performed differential analysis of mRNA expression between GBM and controls in TCGA, GSE16011, and GSE90598. We identified 12,040 DEmRs in TCGA, 9,979 DEmRs in GSE16011, and 9,598 DEmRs in GSE90598 (Figure 3A). Among these DEmRs, 2,369 were all upregulated and 1894 were downregulated in GBM (Figure 3B). These mRNAs may be GBM-associated mRNAs.

To begin to elucidate the consequences of aberrant expression of RBM8A in GBM, we transcriptionally profiled RBM8A-overexpressing (OE) T98G cells and control T98G cells, leading us to identify 9,787 DEmRs (Figure 3C). In addition, we divided the GBM samples in TCGA into RBM8Ahigh and RBM8Alow groups, and we identified 8,260 DEmRs between the two (Figure 3D), of which 1,024 were upregulated and 924 downregulated in the RBM8Ahigh group (Figure 3E). A total of 488 of the DEmRs between RBM8Ahigh and RBM8Alow groups were also DEmRs...
between GBM and controls. These common mRNAs may be associated with both RBM8A expression and GBM tumorigenesis.

**Biological Functions of RBM8A in GBM**

To identify potential roles of RBM8A in GBM, we performed GSEA for GBM and controls. GBM was associated with activation of asthma, p53 signaling, as well as antigen processing and presentation (Supplementary Figure S1A).

Conversely, the disease was associated with suppression of the cAMP signaling pathway, calcium signaling pathway, and retrograde endocannabinoid signaling. We also performed GSEA for RBM8A\textsuperscript{high} and RBM8A\textsuperscript{low} groups. RBM8A\textsuperscript{high} status was associated with activation of hedgehog signaling, Notch signaling, and Fanconi anemia, but with suppression of JAK–STAT signaling, NOD-like receptor signaling, and cytokine-cytokine receptor interaction (Supplementary Figure S1B).
Analysis of the 488 common mRNAs closely related to RBM8A and GBM showed enrichment in activation of neuroblast proliferation and telomere maintenance, but inhibition of T cell apoptosis and response to type I interferon (Figure 4A). Moreover, RBM8A expression correlated positively with inhibition of neuroblast migration but negatively with inhibition of T cell proliferation and cellular potassium ion homeostasis (Figure 4B).

The common mRNAs correlated positively with the KEGG pathways of activated cell cycle and mismatch repair, but negatively with the pathways of activated complement, coagulation, and NOD–like receptor signaling (Figure 4C). RBM8A correlated negatively with inhibition of synaptic vesicle cycling and oxidative phosphorylation (Figure 4D).

**Construction of an RBM8A-Related ceRNA Network**

To identify the regulatory network associated with RBM8A, we first screened for DELncRs in TCGA and GSE16011 that were up-
FIGURE 6 | Identification of candidate mRNAs. (A) The MEGENA coexpression network of common mRNAs. Nodes represent different modules; the larger the node, the greater the number of module genes. (B) Child modules in the MEGENA network featuring the largest number of module genes. Different colors represent different modules, while triangles represent hub genes of modules. (C) Module genes with areas under the receiver operating characteristic curve (AUCs) > 0.95 in both TCGA and GSE16011. (D) Heatmap of 13 genes related to overall survival in RBM8Ahigh and RBM8Alow patients. (E) Selection of the optimal lambda parameter via minimum criteria in the LASSO regression model. (F) LASSO coefficient profiles of 11 genes with non-zero coefficients.
or downregulated in both datasets and were associated with patient survival. In the end, we identified nine upregulated lncRNAs: CRNDE, DLEU1, LEF1-AS1, LINC01426, LINC01516, RARA-AS1, SOX21-AS1, TRAF3IP2-AS1, and ZEB1-AS1. We also identified nine downregulated lncRNAs: CYP1B1-AS1, LGALS8-AS1, LINC01616, LINC02347, LINC02361, LINC02433, MATN1-AS1, RBAKDN, and UNC5B-AS1.

Next we predicted the miRNAs targeted by these 18 lncRNAs using the lncBase 3 database. In GSE90603, we identified 1,389 DEmiRs between GBM and controls (Figure 5A), of which five overlapped with the miRNAs targeted by DElncRs: hsa-miR-124-3p, hsa-miR-128-1-5p, hsa-miR-138-5p, hsa-miR-7-5p, and hsa-miR-15b-5p. We focused on these miRNAs because they may be particularly important in GBM. Using the miRWalk and TargetScan databases, we predicted the mRNAs targeted by these five DEmiRs and identified 161 that overlapped with GBM-associated DEmiRs.

We synthesized the GBM-associated lncRNAs, miRNAs and mRNAs into a ceRNA network (Figure 5B). Four lncRNAs in the network (CRNDE, DLEU1, LEF1-AS1, and LINC01616) were significantly associated with overall survival of GBM patients (Supplementary Figure S2) and were involved mainly in regulating the cell cycle, mitosis, leukocyte activation during immune responses, and DNA replication (Figure 5C). We found that RBM8A may compete with DLEU1 for binding to hsa-miR-128-1-5p (Figure 5D).

Identification of RBM8A-Related Candidate mRNAs

Using MEGENA, we constructed coexpression networks of common mRNAs (Figure 6A). MEGENA identified 37 modules and 336 module genes. Among them, the largest module, C1_5, consisted of 134 genes, while module C1_2 consisted of 96 genes, and C1_14 consisted of 103 genes (Figure 6B). Further, we identified 174 mRNAs whose module
genes had AUCs > 0.7 in both TCGA and GSE16011 (Figure 6C), of which 13 mRNAs were significantly associated with overall survival of GBM patients (Figure 6D). We assessed 11 of these mRNAs as potential prognostic markers in the LASSO algorithm: ANK1, CTNNAL1, EPM2AIP1, FAM20C, GLDN, MRPL17, MYO15A, OPN3, TBR1, TRMT13, and ZNF22 (Figures 6E,F).

We used a multivariate Cox model to build a nomogram (Figure 7A). GBM patients were divided into low- or high-risk groups according to the median risk score based on the candidate mRNAs (Figure 7B). High risk scores were associated with greater risk of mortality. High expression and high risk scores for MYO15A, ANK1, TBR1, GLDN, OPN3, MRPL17, and FAM20C emerged as risk factors. Conversely, high expression and low risk scores for ZNF22, TRMT13, EPM2AIP1, and CTNNAL1 emerged as protective factors.

These results were confirmed by using univariate Cox regression to assess the prognostic value of candidate mRNAs (Figure 7C). In fact, decision curve analysis indicated that candidate mRNAs could diagnose GBM better than either the “all-patients-died” scheme or the “no-patients-died” scheme (Figure 7D).

FAM20C, OPN3, TBR1, ANK1, and MYO15A showed AUCs > 0.5 for predicting overall survival of GBM patients at 1, 3 and 5 years (Supplementary Figure S3). ANK1 and MYO15A showed AUCs > 0.6 for predicting overall survival at the three time points. Candidate mRNAs with AUCs > 0.5 showed a higher average concordance index than other DEmRs (Figure 7E).

Next we trained a predictive model against GDSC data in order to estimate the IC50 for each sample in the RBM8A high and RBM8A low groups. We predicted 12 drugs that might affect genes in the RBM8A high and RBM8A low groups (Figure 7F): AG.014699, PAC.1, JNK.Inhibitor.VIII, Axitinib, ATRA, BAY.61.3606, QS11, PD.173074, ABT.263, BI.D1870, Lenalidomide, and Nilotinib.

**Correlation Between Immune Infiltration and RBM8A Expression in GBM**

According to CIBERSORT, M2 macrophages, CD4+ resting memory T cells and neutrophils had larger specific weights among immune cells in GBM samples than in controls in
TCGA (Figure 8A). The ssGSEA showed that across all three datasets, levels of infiltration by T helper cells, neutrophils, macrophages, CD8 T cells, and activated dendritic cells (aDC) were significantly higher in GBM than in control samples (Figure 8B). The immune cells fell into three clusters (Figure 8C). The RBM8A high group showed strong infiltration by B cells and Tcm cells, and weak infiltration by macrophages, cytotoxic cells, iDC, T cells, neutrophils, and DC. Levels of candidate mRNAs correlated significantly with levels of immune cell infiltration (Figure 8D).

To find out more about the role of RBM8A in immune infiltration, we compared the differences in immune infiltration between the RBM8A high and RBM8A low groups (Figure 9A). In both groups, macrophages correlated strongly with neutrophils (Figure 9B). In RBM8A-overexpressing T98G cells, regulatory T cells had larger specific weight among immune cells (Figure 9C), while DC, iDC, and cytotoxic cells showed less infiltration than in control T98G cells (Figure 9D). These results suggest that aberrant RBM8A expression is associated with immune cell infiltration.

Methylation Modification and Genomic Alterations Associated With Candidate mRNAs in GBM

Comparison of differentially methylated probes (DMPs) between GBM and control samples in TCGA (Figure 10A) allowed us to identify 2,801 upregulated DMPs corresponding to 1,365 genes and 2,033 downregulated DMPs corresponding to 1,705 genes in GBM patients. Among the methylation markers identified in view of opposing methylation levels versus expression levels, GLDN, and TBR1 in candidate mRNAs were subject to methylation modifications (Figure 10B).

Analysis of somatic mutations in GBM samples in TCGA revealed frequent mutations in the PTEN, TP53, TTN, and EGFR genes (Figure 10C). We also detected mutations in the candidate
DISCUSSION

GBM is the most common and aggressive primary brain tumor. Intensive multimodal treatments involving surgery, radiotherapy and chemotherapy have failed to substantially improve median survival (Hasn Mesrati et al., 2020). Elucidating the molecular mechanisms of GBM pathogenesis and finding promising therapeutic targets are essential to improve patient outcomes. Therefore, in this study, we sought to gain a more detailed understanding of the RBM8A-associated regulatory networks and molecular pathways that may affect prognosis. Our results strongly suggest that RBM8A is an important oncogene and may help identify related molecules that could be useful therapeutic targets.

RBM8A is a core component of the exon junction complex (EJC), through which it contributes to the formation and development of the nervous system (McSweeney et al., 2020).
RBM8A deficiency leads to muscle disorganization, neuronal cell death, and motor neuron growth defects (Gangras et al., 2020); conversely, increased RBM8A expression leads to increased proliferation of cells in the ventricular and subventricular zones, while decreasing the migration of cells toward the cortical plate (Zou et al., 2015). Differential expression and dysfunction of EJC core proteins have been reported in multiple cancers (Degot et al., 2004; Kahles et al., 2018; Liu et al., 2020). The results of our analysis show that RBM8A is highly expressed in GBM and positively correlates with tumor purity. Our work provides the first evidence that RBM8A promotes GBM.

In particular, our enrichment analysis linked RBM8A to neuroblast proliferation, telomere maintenance, T cell apoptotic process, and type I interferon in GBM (Mahata et al., 2015; Wang et al., 2016; Feuerbach et al., 2019; Hu et al., 2019). Higher RBM8A expression and GBM appear to be associated with inhibition of neuroblast migration and T cell proliferation. Similarly, RBM8A expression appears to be linked to complement activation, which can promote tumor growth and metastasis (Afshar-Kharghan, 2017). Coagulation factors or their downstream targets can lead to pathophysiology of the central nervous system (De Luca et al., 2017). Dysregulation of NOD-like receptor signaling has been implicated in microbial infection, diabetes, cardiac and metabolic disorders, autoimmune diseases, and cancer (Davis et al., 2011). Indeed, NOD-like receptors may be linked to complement activation, which can promote tumor growth and metastasis (Afshar-Kharghan, 2017). Coagulation factors or their downstream targets can lead to pathophysiology of the central nervous system (De Luca et al., 2017). Dysregulation of NOD-like receptor signaling has been implicated in microbial infection, diabetes, cardiac and metabolic disorders, autoimmune diseases, and cancer (Davis et al., 2011). Indeed, NOD-like receptors may be markers of glioma progression (Sharma et al., 2019). Our previous study confirmed that RBM8A overexpression promoted glioblastoma growth and invasion through the Notch/STAT3 pathway (Lin et al., 2021). The metabolic pathway of oxidative phosphorylation may be a therapeutic target against GBM (Shi et al., 2019; Szmidi et al., 2019).

Our RBM8A-associated ceRNA network suggests that RBM8A competes with DLEU1 for binding to hsa-miR-128-1-5p. DLEU1 has been implicated in the development and progression of several cancers, including GBM (Feng et al., 2019). DLEU1 is upregulated in GBM, and its knockout inhibits GBM cell proliferation and apoptosis, while sensitizing tumor cells to temozolomide (Liu et al., 2019; Lv et al., 2020). Conversely, upregulating hsa-miR-128-1-5p inhibits glioma cell proliferation and promotes apoptosis (Dahai et al., 2020), and the same miRNA has been implicated in hepatocellular carcinoma (Xu et al., 2021). The ceRNA network developed here may help guide future studies of how RBM8A contributes to GBM.

We found that tumor tissues of GBM patients expressing high levels of RBM8A show substantial infiltration by B cells and central memory T cells. This may reflect that GBM is particularly adept at subverting antitumor immunity, leading to profound T cell dysfunction (Woroniecka et al., 2018). GBM can be treated effectively by using immunotherapy to sharpen immune responses against tumors (Wang et al., 2019; Land et al., 2020). Our results may help identify specific T cell subsets and signaling pathways as new therapeutic targets. In addition, our work identified alterations in DNA methylation and somatic mutations that suggest the possibility of additional therapeutic targets that should be explored.

Nevertheless, our study does have some limitations. First, the RBM8A-related risk score model requires further validation in multicenter clinical trials and prospective studies. Indeed, the candidate mRNAs should be verified and analyzed in detail in cellular and biochemical studies. In fact, the network of lncRNAs, miRNAs, and mRNAs described here should be explored in order to establish the full range of processes through which RBM8A may influence GBM onset and progression. In addition, there are some limitations in this study. The role of RBM8A on chemotherapy resistance has not been addressed in current study, which will be pursued in future studies. The hedgehog, and JAK–STAT pathways need to be supported by functional studies in future.

**CONCLUSION**

We found that RBM8A may be a diagnostic marker, oncogene and therapeutic target in GBM. We established and validated a risk score model based on 11 candidate mRNAs that can reliably predict overall survival of GBM patients. This work may move us closer to individualized treatment and management of GBM as well as more detailed understanding of its pathology.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

**ETHICS STATEMENT**

This study was approved by the Ethics Committee of the Fifth Affiliated Hospital of Guangxi Medical University.

**AUTHOR CONTRIBUTIONS**

LW, CZ, LC, YM, and DZ designed the study and contributed to drafting the manuscript. YL, CZ, LC, LL, LW, BH, YM, and DZ...
performed experiments, and collated and analyzed the data. YM and DZ reviewed and revised the manuscript. All authors read and approved the final submitted manuscript.

**FUNDING**

This study was supported by the Scientific Research Project of Guangxi Health Commission (Nos Z2015285, Z20190684, Z20210933, and Z20210139) and the High-Level Medical Expert Training Program of the Guangxi “139” Plan (G2019103049).

**REFERENCES**

Afsar-Kharghan, V. (2017). The Role of the Complement System in Cancer. *J. Clin. Invest.* 127 (3), 780–789. doi:10.1172/JCI90962

Dahai, Z., Dalig, C., Fanu, L., Xiang, W., Lenian, L., Jiannin, C., et al. (2020). Lowly Expressed IncRNA PVT1 Suppresses Proliferation and Advances Apoptosis of Glioma Cells through Up-Regulating microRNA-128-1-5p and Inhibiting PTBP1. *Brain Res. Bull.* 163, 1–13. doi:10.1016/j.brainresbull.2020.06.006

Davis, B. K., Wen, H., and Ting, J. P.-Y. (2011). The Inflammatory Role of M1 Macrophages in Central Nervous System Diseases. *Annu. Rev. Immunol.* 29, 707–735. doi:10.1146/annurev-immunol-031210-101405

De Luca, C., Virtuo, A., Maggio, N., and Papa, M. (2017). Neuro-Coagulopathy: Blood Coagulation Factors in Central Nervous System Diseases. *Int. J. Mol. Sci.* 18 (10), 2128. doi:10.3390/ijms18102128

Degot, S., Le Hir, H., Alpy, F., Kedinger, V., Stoll, I., Wendling, C., et al. (2004). Association of the Breast Cancer Protein MLN51 with the Exon junction Complex via its Speckle Localiser and RNA Binding Module. *J. Biol. Chem.* 279 (32), 33702–33715. doi:10.1074/jbc.m402754200

Fathi Kazerooni, A., Bakas, S., Saligheh Rad, H., and Davatzikos, C. (2020). Imaging Signatures of Glioblastoma Molecular Characteristics: A Radiogenomics Review. *J. Magn. Reson. Imaging* 52 (1), 54–69. doi:10.1002/jmri.26097

Feng, L., He, M., Rao, M., Diao, J., and Zhu, Y. (2019). Long Noncoding RNA DLEU1 Aggravates Glioma Progression via the miR-421/MIF2D axis. *Otol. Vol. 12, 5405–5414. doi:10.2174/otv.201707542

Feuerbach, L., Sieverling, L., Deeg, K. I., Ginsbach, P., Hutter, B., Buchhalter, I., et al. (2019). TelomereHunter - In Silico Estimation of Telomere Content and Composition from Cancer Genomes. *BMC Bioinformatics* 20 (1), 272. doi:10.1186/s12859-019-2851-0

Friedman, J., Hastie, T., and Tibshirani, R. (2010). Regularization Paths for Generalized Linear Models via Coordinate Descent. *J. Stat. Softw.* 33 (1), 1–22. doi:10.18637/jss.v033.i01

Gapranga, P., Gallagher, T. L., Parthum, M. A., Yi, Z., Paton, R. D., Tietz, K. T., et al. (2020). Zebrafish Rbm8a and Magoh Mutants Reveal EJC Developmental Functions and New 3’UTR Intron-Containing NMD Targets. *Plos Genet.* 16 (6), e1008830. doi:10.1371/journal.pgen.1008830

Gasparoni, G., Bultmann, S., Lutsik, P., Krcaus, T. F. J., Sordon, S., Vlcek, J., et al. (2018). DNA Methylation Analysis on Purified Neurons and Glia Dissects Age and Alzheimer’s Disease-specific Changes in the Human Cortex. *Epigenetics & Chromatin* 11 (1), 41. doi:10.1186/s13072-018-0211-3

Hallal, S., Ebrahim Khan, S., Wei, H., Lee, M. Y.-T., Sim, H. W., Sy, J., et al. (2020). Deep Sequencing of Small RNAs from Neurosurgical Extracellular Vesicles Substantiates miR-486-3p as a Circulating Biomarker that Distinguishes Glioblastoma from Lower-Grade Astrocytoma Patients. *Int. J. Mol. Sci.* 21 (14), 4954. doi:10.3390/ijms21144954

Hanzelmann, S., Castelo, R., and Guinney, J. (2013). GSVA: Gene Set Variation Analysis for Microarray and RNA-Seq Data. *BMC Bioinformatics* 14, 7. doi:10.1186/1471-2105-14-7

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmobi.2022.876603/full#supplementary-material

**Supplementary Figure S1** | (A). GSEA comparing GBM and controls. (B). GSEA comparing RBM8A−/− and RBM8A+/+ groups.

**Supplementary Figure S2** | Association of long noncoding RNAs in the ceRNA network with overall survival of GBM patients.

**Supplementary Figure S3** | Ability of candidate mRNAs to predict overall survival at one, three or five years, based on the area under receiver operating characteristic curves (AUC). Only mRNAs showing AUCs >0.6 in TCGA are shown.
